| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $10,042 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Morris Gabriel S | CFO | 1 | $5,067 | 0 | $0 | $5,067 |
| Rachman Ilya M | CEO and Chairman | 1 | $4,976 | 0 | $0 | $4,976 |
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic …
Over the last 12 months, insiders at Immix Biopharma, Inc. have bought $10,042 and sold $0 worth of Immix Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Immix Biopharma, Inc. have bought $270,856 and sold $550 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Morris Gabriel S (CFO) — $5,067. Rachman Ilya M (CEO and Chairman) — $4,976.
The last purchase of 746 shares for transaction amount of $4,976 was made by Rachman Ilya M (CEO and Chairman) on 2025‑12‑10.
| 2025-12-10 | Rachman Ilya M | CEO and Chairman | 746 0.0022% | $6.67 | $4,976 | +32.84% | ||
| 2025-12-10 | Morris Gabriel S | CFO | 770 0.0023% | $6.58 | $5,067 | +32.84% | ||
| 2025-09-17 | Rachman Ilya M | CEO and Chairman | 2,500 0.0089% | $2.02 | $5,050 | +332.14% | ||
| 2025-09-16 | Morris Gabriel S | CFO | 2,600 0.0089% | $1.97 | $5,122 | +322.50% | ||
| 2025-06-18 | Rachman Ilya M | CEO and Chairman | 2,178 0.0075% | $2.29 | $4,999 | +107.53% | ||
| 2025-06-18 | Morris Gabriel S | CFO | 2,225 0.0076% | $2.28 | $5,071 | +107.53% | ||
| 2024-12-23 | Hsu Jason | director | 40,000 0.1423% | $2.19 | $87,680 | +0.46% | ||
| 2024-12-20 | Hsu Jason | director | 7,700 0.028% | $2.17 | $16,678 | +0.92% | ||
| 2024-08-22 | Hsu Jason | director | 8,100 0.0301% | $2.25 | $18,233 | -9.95% | ||
| 2024-08-21 | Hsu Jason | director | 15,000 0.0533% | $2.23 | $33,390 | -12.72% | ||
| 2024-08-16 | Ng Carey | director | 10,000 0.0379% | $1.86 | $18,600 | +4.74% | ||
| 2024-07-24 | Hsu Jason | director | 6,000 0.0237% | $2.15 | $12,877 | -4.37% | ||
| 2024-07-18 | Hsu Jason | director | 3,200 0.0123% | $2.07 | $6,639 | -3.90% | ||
| 2024-06-07 | Rachman Ilya M | CEO and Chairman | 2,600 0.0103% | $2.13 | $5,538 | -2.96% | ||
| 2024-06-07 | Morris Gabriel S | CFO | 2,500 0.0099% | $2.12 | $5,298 | -2.96% | ||
| 2024-06-04 | Rachman Ilya M | CEO and Chairman | 3,300 0.0125% | $1.81 | $5,970 | +8.84% | ||
| 2024-06-04 | Morris Gabriel S | CFO | 3,300 0.0125% | $1.81 | $5,973 | +8.84% | ||
| 2024-05-14 | Rachman Ilya M | CEO and Chairman | 4,300 0.0166% | $2.25 | $9,660 | -10.45% | ||
| 2024-05-14 | Morris Gabriel S | CFO | 4,500 0.0173% | $2.23 | $10,042 | -10.45% | ||
| 2023-12-11 | Hsu Jason | director | 31,000 0.1596% | $4.67 | $144,894 | -52.81% |
| Rachman Ilya M | CEO and Chairman | 1141683 1.3771% | $8.8M | 8 | 0 | +72.52% |
| Morris Gabriel S | CFO | 291429 0.3515% | $2.25M | 8 | 0 | +71.14% |
| Torchilin Vladimir P | Scientific Co-Founder | 905200 1.0919% | $6.98M | 2 | 0 | <0.0001% |
| Hsu Jason | director | 893000 1.0772% | $6.89M | 14 | 0 | <0.0001% |
| BUCHAN MELISSA JANE | director | 20000 0.0241% | $154,200.00 | 1 | 0 | +16.87% |
| Marquet Magda | director | 20000 0.0241% | $154,200.00 | 3 | 0 | +25.6% |
| Ng Carey | director | 20000 0.0241% | $154,200.00 | 3 | 0 | <0.0001% |
| Adams Helen C. | director | 13000 0.0157% | $100,230.00 | 1 | 0 | +4.32% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
Immix Biopharma, Inc. (IMMX) | $1,344,238 | 38 | 23.07% | $639.18M |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 58 | +232% | 22M | +785.64% |
| Decreased Positions | 11 | -44% | 113,501 | -4.1% |
| New Positions | 41 | New | 18M | New |
| Sold Out Positions | 5 | Sold Out | 38,790 | Sold Out |
| Total Postitions | 72 | +188% | 24M | +781.54% |
| Bleichroeder Lp | $4,616.00 | 1.6% | 850,000 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,965.00 | 1.38% | 730,162 | +31,625 | +4.53% | 2025-09-30 |
| Geode Capital Management, Llc | $1,018.00 | 0.35% | 187,476 | +26,361 | +16.36% | 2025-09-30 |
| Morgan Stanley | $655.00 | 0.23% | 120,670 | -4,249 | -3.4% | 2025-09-30 |
| State Street Corp | $537.00 | 0.19% | 98,960 | +56,000 | +130.35% | 2025-09-30 |
| Susquehanna International Group, Llp | $493.00 | 0.17% | 90,858 | +40,032 | +78.76% | 2025-09-30 |
| Citadel Advisors Llc | $488.00 | 0.17% | 89,798 | +89,798 | New | 2025-09-30 |
| Northern Trust Corp | $485.00 | 0.17% | 89,301 | -4,587 | -4.89% | 2025-09-30 |
| United Capital Financial Advisors, Llc | $384.00 | 0.13% | 70,682 | +70,682 | New | 2025-09-30 |
| Imprint Wealth Llc | $366.00 | 0.13% | 67,423 | +41,209 | +157.2% | 2025-09-30 |